Milestone falls after FDA refuses to review marketing application for nasal spray

Milestone Pharmaceuticals

26/12/2023 13:00

** Shares of Milestone Pharmaceuticals  MIST.O  fall 25.4%
to $2.15 premarket
    ** Co says the U.S. FDA refused to review its marketing
application for a nasal spray in the treatment of paroxysmal
supraventricular tachycardia, a type of abnormal heart rhythm
    ** Says the FDA requested time of data recorded for adverse
events in late-stage clinical trials for the treatment
    ** MIST says it will work with the FDA to understand the
issues and to agree on a path forward
    ** Up to last close, stock down ~27.3% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))